BIOTRONIK Driving the Future of Active Device Business Company to divest its Vascular Intervention Business Division to Teleflex Inc.
BIOTRONIK, a global leader in medical technology, and a pioneer in cardiovascular, endovascular, and neuromodulation solutions, today announced a strategic shift to strengthen its leadership in active implantable devices and digital healthcare.
Leveraging future technologies, including artificial intelligence (AI), remote patient monitoring and connected healthcare platforms, BIOTRONIK is at the forefront of improving patient outcomes and optimizing clinical workflows. These innovations are designed to enhance the efficiency and accessibility of care, enabling healthcare providers with next-generation tools for personalized, cost-effective treatments.
As part of this strategy, BIOTRONIK has entered into an agreement to divest its Vascular Intervention (VI) division to Teleflex Incorporated (NYSE: TFX), a global leader in medical technologies. The transaction, pending regulatory approval, is targeted to close latest in the third quarter of 2025. The two companies will collaborate closely to ensure smooth transition and a successful outcome.
This strategic move reflects the company’s long-term commitment to active implantable devices that address critical healthcare challenges, such as aging populations, shrinking care budgets, and resource limitations. With a strong focus on active devices and digital health solutions, BIOTRONIK is advancing technologies to drive innovation and play a leading role in shaping the future of healthcare.
The Vascular Intervention business stands as a leader in interventional therapies with revolutionary products including the Orsiro drug-eluting stent, PK Papyrus - a lifesaving covered stent for artery perforations and Freesolve - resorbable magnesium scaffold amongst many other offerings. This highly attractive portfolio will complement Teleflex’s interventional business, enabling both companies to deliver enhanced solutions to global markets.
“We are incredibly proud of the transformative contributions our Vascular Intervention division has made to interventional therapies and patient care worldwide,” said Dr. Alexander Uhl, CEO of BIOTRONIK Group. “As healthcare continues to rapidly evolve, our focus is firmly on advancing AI-driven technologies that meet the needs of both patients and clinicians in the years to come. This strategic shift empowers us to amplify our investments in emerging technologies across Cardiac Rhythm Management, Patient Monitoring, Heart Failure, and Neuromodulation therapies. We will transform the future of healthcare innovation in these critical areas.”
BIOTRONIK is dedicated to delivering precision-engineered products, cutting-edge offerings, and exceptional service. With over 60 years of German expertise, the company is recognized for its continuous innovation and uncompromising quality. By sharpening its focus on active implantable devices and digital health solutions, BIOTRONIK is driving the next era of healthcare technology.
-END-
About BIOTRONIK:
At BIOTRONIK, patient well-being is our top priority and has been for over 60 years. BIOTRONIK is a leading global medical technology company with products and offerings that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular, endovascular and neuromodulation therapies. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries across the Americas, EMEA (Europe, the Middle East, and Africa), and Asia-Pacific.